hVIVO's Mo Khan on the company’s breakthrough year
Episode 1143, Jan 25, 2023, 11:19 AM
Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist hVIVO, about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.
Watch the video interview HERE
0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance
2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models
6:35 hVivo’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
8:04 Discusses the recent Venn Life Sciences consultancy contract win
9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth
Watch the video interview HERE
0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance
2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models
6:35 hVivo’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
8:04 Discusses the recent Venn Life Sciences consultancy contract win
9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth